Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
331 EUR | -.--% | -.--% | -.--% |
04/06 | GENMAB A/S : Truist Securities handhaaft koopadvies | ZM |
03/06 | Tisotumab van Genmab vertoont 'bemoedigende' antitumoractiviteit in fase 2-studie naar hoofd-halskanker | MT |
Omzet 2024 * | 19,8 mld. 2,89 mld. 2,65 mld. | Omzet 2025 * | 23,62 mld. 3,45 mld. 3,16 mld. | Marktkapitalisatie | 124 mld. 18,16 mld. 16,67 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 4,68 mld. 683 mln. 627 mln. | Nettowinst (verlies) 2025 * | 6,61 mld. 965 mln. 886 mln. | EV/omzet 2024 * | 4,98 x |
Nettoliquiditeiten 2024 * | 25,92 mld. 3,78 mld. 3,47 mld. | Nettoliquiditeiten 2025 * | 32,36 mld. 4,72 mld. 4,33 mld. | EV/omzet 2025 * | 3,9 x |
K/w-verhouding 2024 * |
28,4
x | K/w-verhouding 2025 * |
20,5
x | Werknemers | 2.286 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 98,51% |
Recentste transcriptie over Genmab A/S
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 63 | 01-01-99 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 01-01-07 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 23-03-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 01-01-17 |
Director/Board Member | 73 | 01-11-03 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 01-01-16 |
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+16,73% | 121 mld. | |
+13,04% | 107 mld. | |
-5,80% | 24,82 mld. | |
+1,69% | 22,48 mld. | |
-40,52% | 16,33 mld. | |
-14,00% | 15,31 mld. | |
+1,18% | 14,08 mld. | |
+24,18% | 11,74 mld. | |
+83,67% | 9,02 mld. |
- Beurs
- Aandelen
- Koers GMAB
- Koers GE9